← Evidence map

ArticleMayo Clinic proceedings. Innovations, quality & outcomes2026

Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System.

Magdi Elsallab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System. | OpenQuestion